Skip to Content

Research

POSITIVE

Research

Research

Clinicaltrial.gov identifier:
NCT02308085
Status:
Recruiting
Scenario:
Study, no CT no PAS (Post-Approval Studies), without drug
Tumour subtype:
HR+
Drug/Intervention:
Endocrine therapy interruption

Endocrine therapy interruption to enable conception for young women with ER+ breast cancer

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).

Collaborators

NCIC Clinical Trials Group
Alliance for Clinical Trials in Oncology

Principal investigators

Dr. Olivia Pagani, MD

Oncology Institute of Southern Switzerland (IOSI)

Dr. Ann Partridge MD MPH

Dana-Farber Cancer Institute

Dr. Hatem A. Azim Jr., MD, PhD

BrEAST Data Centre, Department of Medicine, Institut Jules Bordet

Dr. Fedro Peccatori, MD, PhD

Division of Gynecologic Oncology, European Inst

X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.